Sareum Holdings PLC Reference to SRA737 Timeline at Cantor Conference (3849N)
29 Septiembre 2021 - 4:46AM
UK Regulatory
TIDMSAR
RNS Number : 3849N
Sareum Holdings PLC
29 September 2021
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Reference to Potential SRA737 Clinical Development Timeline in
Sierra Oncology Investor Presentation at 2021 Cantor Virtual Global
Healthcare Conference
Cambridge, UK, 29 September 2021 - Sareum Holdings plc (AIM:
SAR), the specialist drug development company, notes that Sierra
Oncology, the licence holder for SRA737 (a novel Chk1 inhibitor),
presented at 21.00 BST on 28 September at the 2021 Cantor Virtual
Global Healthcare Conference in a Fireside Chat. During this
conference and included in a slide of recent and upcoming
milestones, Sierra Oncology's CEO, Stephen Dilly, referred to the
initiation of additional clinical studies with pipeline agents
including SRA737 in other haematologic and solid tumour indications
in the first half of 2022.
Specifically, reference was made to a potential role for SRA737
in combination studies in solid tumours, including pancreatic
cancer, where patients have become resistant to PARP
inhibitors.
In a previous discussion, noted by Sareum on 6 August 2021, of
the rationale for in-licensing BET inhibitor AZD5153, now known as
SRA515, from AstraZeneca, Sierra referred to possible pipeline
expansion opportunities in other haematologic or solid tumour
indications. These included potential combinations with SRA737,
immune-oncology agents, PARP inhibitors and drugs with other
mechanisms of action. Sierra has also noted that SRA515 has shown
preclinical efficacy in combination with a diverse range of agents,
and that synergy between SRA515 and a family of DNA damage response
agents, known as ATR inhibitors, suggested potential utility in
combination with SRA737.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed to Sierra in September 2016.
Sareum's CEO, Dr Tim Mitchell, commented :
"This timeline for the possible initiation of combination
studies by Sierra including SRA737 in the first half of 2022 is
very encouraging and would represent a significant advance in the
development of the SRA737 programme. We look forward to further
updates on the clinical development of SRA737, a molecule that has
shown great promise in clinical trials and preclinical studies,
particularly in combination with other types of cancer
therapy."
A recording of Sierra Oncology's fireside chat at the 2021
Cantor Virtual Global Healthcare Conference can be found at
www.sierraoncology.com
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
MEDiSTRAVA Consulting (Financial
PR)
Mark Swallow / David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUACBUPGUBB
(END) Dow Jones Newswires
September 29, 2021 05:46 ET (09:46 GMT)
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024